STOCK TITAN

Tenax Therapeutics: BVF Partners reports ~9.99% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

TENAX THERAPEUTICS, INC. (TENX) common stock is the subject of an amended beneficial-ownership report by Biotechnology Value Fund, L.P., related funds and managers, and Mark N. Lampert. BVF Partners L.P., BVF Inc., and Lampert each may be deemed to beneficially own the same 4,150,818 shares, or approximately 9.99%, through shared voting and dispositive power. Lampert is identified as a director and officer of BVF Inc.; the report says these attributions are not admissions of ownership of shares held by other reporting persons.

As of September 30, 2026, the reporting persons and a managed account held pre-funded warrants exercisable for 6,376,216 shares. Each warrant is immediately exercisable for one share at $0.01 and has no expiration date. A 9.99% ownership blocker limited their exercise to 4,125,818 shares as of that date. The ownership percentages use 37,423,917 shares outstanding as of July 28, 2026, plus the shares issuable under the warrants included in the calculation.

Beneficially owned shares 4,150,818 shares Amount attributed to BVF Partners L.P., BVF Inc., and Mark N. Lampert as of September 30, 2026; the attributions overlap.
Beneficial ownership percentage Approximately 9.99% Reported for BVF Partners L.P., BVF Inc., and Mark N. Lampert as of September 30, 2026.
Shares underlying pre-funded warrants 6,376,216 shares Warrants held by the reporting persons and the Partners Managed Account as of September 30, 2026.
Shares exercisable under blocker 4,125,818 shares Amount the reporting persons and the Partners Managed Account could exercise under the blocker as of September 30, 2026.
Warrant exercise price $0.01 per share Each pre-funded warrant is exercisable for one common share.
Shares outstanding 37,423,917 shares As of July 28, 2026; used with issuable warrant shares to calculate reported ownership percentages.
BVF beneficial ownership 3,356,851 shares Approximately 8.2% of outstanding shares as of September 30, 2026, including shares underlying certain pre-funded warrants.
beneficial ownership regulatory
"Amount beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Pre-Funded Warrants financial
"The Pre-Funded Warrants are immediately exercisable"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Pre-Funded Warrants Blocker regulatory
"The exercise of the Pre-Funded Warrants is subject to the limitations"
shared voting power regulatory
"Shared Voting Power 4,150,818.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 4,150,818.00"
Attribution Parties regulatory
"together with its Attribution Parties"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TENX shares do the reporting persons beneficially own?

The reported amount is 4,150,818 shares, or approximately 9.99%, for BVF Partners L.P., BVF Inc., and Mark N. Lampert, each of whom may be deemed to beneficially own the same shares through shared voting and dispositive power. These are overlapping attributions, not separate holdings to add together. Lampert is identified as a director and officer of BVF Inc.

How many TENX pre-funded warrant shares can the reporting persons exercise?

As of September 30, 2026, the 9.99% Pre-Funded Warrants Blocker limited exercise by the reporting persons and the Partners Managed Account to 4,125,818 shares out of 6,376,216 shares underlying their warrants. The blocker applies when exercise would result in beneficial ownership above 9.99% immediately after exercise.

What are the exercise terms for the TENX pre-funded warrants?

Each pre-funded warrant is exercisable for one TENX common share at an exercise price of $0.01 per share. The warrants are immediately exercisable and have no expiration date, subject to the 9.99% ownership blocker.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





88032L605

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:11/16/2026

Keep reading